# US 2009/0221507 A1 · Compositions and Methods for Treating Nervous System Disorders

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0221507 A1
- Document ID: US20090221507A1
- Status: Published application
- Kind: A1
- Application number: 12/067,792
- Filed: 2006-09-25
- Published: 2009-09-03
- Earliest claimed: 2005-09-23
- Assignees: The Regents of the University of California
- Inventors: Katerina Akassoglou
- Web page: https://patentgrep.com/patent/US20090221507A1

## CPC

- C07K 16/36: against blood coagulation factors
- A61K 38/363: {Fibrinogen}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention herein related to methods and compositions for treating nervous system disorders. The methods comprise peptides that bind to receptors important in disease progression, thus attenuating the disease.

## Claims

### Claim 1

A method of treating a degenerative disorder of the nervous system, the method comprising administering to a mammalian subject a therapeutically effective amount of a composition comprising a peptide consisting essentially of about 19 amino acids and having at least about 90% sequence identity with the peptide sequence tyr-ser-met-lys-lys-thr-thr-met-lys-ile-ile-pro-phe-asn-arg-leu-thr-ile-gly (YSMKKTTMKIIPFNRLTIG) (SEQ ID NO: 1).

### Claim 2 (depends on 1)

A method according to claim 1, wherein the peptide consists essentially of the sequence YSMKKTTMKIIPFNRLTIG (SEQ ID NO: 1).

### Claim 3 (depends on 1)

A method according to claim 1, wherein the peptide consists of the sequence YSMKKTTMKIIPFNRLTIG (SEQ ID NO: 1).

### Claim 4 (depends on 1)

A method according to claim 1, wherein the disorder is selected from the group consisting of multiple sclerosis, spinal cord injury, stroke and Alzheimer's Disease.

### Claim 5 (depends on 1)

A method according to claim 1, wherein the disorder is multiple sclerosis.

### Claim 6

A composition for the treatment of a degenerative disorder of the nervous system, the composition comprising:
a peptide consisting essentially of about 19 amino acids and having at least about 90% sequence identity with the peptide sequence YSMKKTTMKIIPFNRLTIG (SEQ ID NO: 1); and
a pharmaceutically acceptable excipient.

### Claim 7 (depends on 6)

A composition according to claim 6, wherein the peptide consists essentially of the sequence YSMKKTTMKIIPFNRLTIG (SEQ ID NO: 1).

### Claim 8 (depends on 6)

A composition according to claim 6, wherein the peptide consists of the sequence YSMKKTTMKIIPFNRLTIG (SEQ ID NO: 1).

### Claim 9 (depends on 6)

A composition according to claim 6, wherein the disorder is selected from the group consisting of multiple sclerosis, spinal cord injury, stroke and Alzheimer's Disease.

### Claim 10 (depends on 6)

A composition according to claim 6, wherein the disorder is multiple sclerosis.

### Claim 11

(canceled)

### Claim 12

(canceled)

### Claim 13

(canceled)

### Claim 14

A method of inhibiting microglia activation, the method comprising contacting the microglia with a composition comprising a peptide consisting essentially of about 19 amino acids and having at least about 90% sequence identity with the peptide sequence YSMKKTTMKIIPFNRLTIG (SEQ ID NO: 1).

### Claim 15 (depends on 14)

A method according to claim 14, wherein the peptide consists essentially of the sequence YSMKKTTMKIIPFNRLTIG (SEQ ID NO: 1).

### Claim 16 (depends on 14)

A method according to claim 14, wherein the peptide consists of the sequence YSMKKTTMKIIPFNRLTIG (SEQ ID NO: 1).

### Claim 17 (depends on 14)

A method according to claim 14, wherein the microglia are microglia comprised by a mammalian subject.

### Claim 18 (depends on 14)

A method according to claim 14, wherein the mammalian subject is a human in need of treatment for a degenerative neurological disease.

### Claim 19 (depends on 18)

A method according to claim 18, wherein the degenerative neurological disease is selected from the group consisting of multiple sclerosis, spinal cord injury, stroke and Alzheimer's Disease.

### Claim 20 (depends on 14)

A method according to claim 14, wherein the peptide is comprised by a composition further comprising a pharmaceutically acceptable excipient.

### Claim 21

A method of preventing development of a neurological disorder, the method comprising administering to a subject an effective amount of a composition comprising a peptide consisting essentially of about 19 amino acids and having at least about 90% sequence identity with the peptide sequence tyr-ser-met-lys-lys-thr-thr-met-lys-ile-ile-pro-phe-asn-arg-leu-thr-ile-gly (YSMKKTTMKIIPFNRLTIG) (SEQ ID NO: 1).

### Claim 22 (depends on 21)

A method according to claim 21, wherein the peptide consists essentially of the sequence YSMKKTTMKIIPFNRLTIG (SEQ ID NO: 1).

### Claim 23 (depends on 21)

A method according to claim 21, wherein the peptide consists of the sequence YSMKKTTMKIIPFNRLTIG (SEQ ID NO: 1).

### Claim 24 (depends on 21)

A method according to claim 21, wherein the disorder is selected from the group consisting of multiple sclerosis, spinal cord injury, stroke and Alzheimer's Disease.

### Claim 25 (depends on 21)

A method according to claim 21, wherein the disorder is multiple sclerosis.

### Claim 26

An isolated antibody that binds a peptide consisting essentially of about 19 amino acids and having at least about 90% sequence identity with the peptide sequence tyr-ser-met-lys-lys-thr-thr-met-lys-ile-ile-pro-phe-asn-arg-leu-thr-ile-gly (YSMKKTTMKIIPFNRLTIG) (SEQ ID NO: 1), or a fragment thereof.

### Claim 27 (depends on 26)

The antibody of claim 26, wherein the antibody is a monoclonal antibody.

### Claim 28 (depends on 26)

The antibody of claim 26, wherein said antigen-binding fragment is a fragment selected from the group consisting of Fab, Fab′, F(ab′)2 and F(v).
